Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells
Journal
Journal of Urology
Journal Volume
165
Journal Issue
6 I
Pages
[d]2082-2085
Date Issued
2001
Author(s)
Abstract
Purpose: We studied the cross-resistance and combined cytotoxic effects of cisplatin and paclitaxel in bladder cancer cells in vitro. Materials and Methods: The cytotoxicity of the 2 agents alone or in combination were studied in the bladder cancer cell line NTUB1 and the 2 sublines NTUB1/P, which is cisplatin resistant, and NTUB1/T, which is paclitaxel resistant, using the microculture tetrazolium assay. Schedule dependence of the 2-drug combination was assayed using 3 treatment schedules, including 1 concurrent and 2 sequential exposures. Results: The mean cisplatin concentration plus or minus standard error of the means inhibiting 50% of the growth of NTUB1, NTUB1/P and NTUB1/T was 1.9 ± 0.19, 19.3 ± 2.33 and 2.1 ± 0.15 μM., respectively, and the mean paclitaxel concentration inhibiting 50% of the growth of the 3 cell lines was 30 ± 3.9, 1,033 ± 120 and 110 ± 15 nM., respectively. NTUB1/P had strong cross-resistance to paclitaxel. In contrast, NTUB1/T was as sensitive as NTUB1 to cisplatin. On median effect analysis the combined effects of the 2 agents given concurrently were sub-additive in the low fraction affected range of 0.1 to 0.3 and additive in the median to high fraction affected range of 0.4 to 1.0 in the 3 cell lines. Combined cytotoxicity was more synergistic when paclitaxel was given 24 hours earlier than cisplatin. The effects were less synergistic when cisplatin was given before paclitaxel. This phenomenon was noted in sensitive and resistant cells. Conclusions: In our bladder cancer cell model cisplatin resistant cells have strong cross-resistance to paclitaxel, whereas paclitaxel resistant cells are sensitive to cisplatin. The combined effects may be optimized by sequential use of the 2 agents, preferably paclitaxel given 24 hours before cisplatin. Our results have clinical implications for the treatment of bladder cancer.
SDGs
Other Subjects
cisplatin; paclitaxel; tetrazolium; antineoplastic agent; cisplatin; paclitaxel; article; bladder cancer; cancer cell; cancer growth; concentration response; controlled study; cross resistance; drug cytotoxicity; drug effect; drug potentiation; drug sensitivity; growth inhibition; human; human cell; minimum inhibitory concentration; priority journal; bladder tumor; cell culture; salvage therapy; transitional cell carcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Drug Synergism; Humans; Paclitaxel; Salvage Therapy; Tumor Cells, Cultured; Urinary Bladder Neoplasms
Publisher
Lippincott Williams and Wilkins
Type
journal article